The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease

Diabetes Res Clin Pract. 2020 Jul:165:108223. doi: 10.1016/j.diabres.2020.108223. Epub 2020 May 28.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Cost-Benefit Analysis
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Pioglitazone / therapeutic use
  • Thiazolidinediones*

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Pioglitazone